ACADIA PHARMACEUTICALS INC
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
ACAD$18.28+10.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities | ||
| Net income (loss) | $16,555 | $(43,021) |
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | ||
| Stock-based compensation | 14,750 | 14,705 |
| Amortization of premiums and accretion of discounts on investment securities | (1,786) | (2,267) |
| Amortization of intangible assets | 5,286 | — |
| Gain on strategic investment | — | (4,845) |
| Loss on sale of investment securities | — | 505 |
| Depreciation | 242 | 426 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | 3,566 | (3,720) |
| Interest and other receivables | (1,295) | (3,450) |
| Inventory | (16,648) | 481 |
| Prepaid expenses | (3,670) | (2,234) |
| Operating lease right-of-use assets | 1,759 | 1,726 |
| Accounts payable | 1,789 | 4,676 |
| Accrued liabilities | 12,193 | 24,510 |
| Operating lease liabilities | 212 | (1,656) |
| Long-term liabilities | (3,874) | (3,769) |
| Net cash provided by (used in) operating activities | 29,079 | (17,933) |
| Cash flows from investing activities | ||
| Purchases of investment securities | (80,154) | (66,892) |
| Sale and maturity of investment securities | 66,115 | 259,410 |
| Net cash (used in) provided by investing activities | (14,039) | 192,518 |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock, net of issuance costs | 1,043 | 1,466 |
| Net cash provided by financing activities | 1,043 | 1,466 |
| Effect of exchange rate changes on cash | 5 | (2) |
| Net increase in cash, cash equivalents and restricted cash | 16,088 | 176,049 |
| Cash, cash equivalents and restricted cash | ||
| Beginning of period | 194,427 | 120,616 |
| End of period | $210,515 | $296,665 |
| Supplemental disclosure of noncash information: | ||
| Accrued inventory purchases | $9,354 | $— |
| Accrued milestone and contingent payments in connection with asset acquisition | $50,000 | $69,583 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.